FDA Approves Sunharbo to Reduce Stroke Risk
The first factor XIa inhibitor to win approval is cleared for recent mild-to-moderate non-cardio-embolic ischaemic stroke or high-risk transient ischaemic attack patients.
Updated on Nov. 18, 2026 in Stroke

The U.S. Food and Drug Administration approved Bayer's asundexian, sold under the brand name Sunharbo, to reduce stroke risk in certain patients. It is approved in combination with standard-of-care antiplatelet therapy for people who recently had a mild-to-moderate non-cardio-embolic ischaemic stroke or a high-risk transient ischaemic attack.
Why it matters
Antiplatelet therapies cannot always be used long term because of their bleeding risk, so a new option aimed at reducing recurrent stroke could widen treatment choices. The approval also bodes well for milvexian and abelacimab, which are in phase 3 development.
The FDA decision rests on the phase 3 OCEANIC-STROKE trial, in which Sunharbo added to antiplatelet therapy cut ischaemic stroke by 26% versus antiplatelet therapy alone across more than 12,000 people, with major bleeding at 1.9% versus 1.7% for placebo. The FDA flagged higher major bleeding in patients over 75 and during the first 90 days of treatment, and the drug is not approved for atrial fibrillation patients.
The players
Bayer
Bayer is a German multinational pharmaceutical and life sciences company that developed asundexian.
U.S. Food and Drug Administration
The FDA is the U.S. federal agency responsible for approving prescription drugs and medical products for sale in the United States.
The details
Sunharbo blocks an enzyme involved in excessive blood clotting without interfering with normal physiological healing mechanisms. Trial participants had a qualifying non-cardio-embolic ischaemic stroke or high-risk transient ischaemic attack within the preceding 72 hours before enrollment.
Timeline
Within 72 hours before enrollment: OCEANIC-STROKE participants' qualifying stroke or TIA occurred.
First 90 days of treatment: Major bleeding was higher with Sunharbo.
November 18, 2026: FDA approval of Sunharbo reported.
Health Landscape
Sunharbo extends the antiplatelet standard of care for secondary stroke prevention by adding a factor XIa inhibitor on top of existing therapy, where antiplatelets alone are constrained by bleeding risk. It becomes the first approved drug in its class, opening a path for competing candidates like milvexian and abelacimab now in phase 3 development.
For people who have recently had a mild-to-moderate ischaemic stroke or high-risk TIA, Sunharbo offers an added option alongside standard antiplatelet therapy, with a list price of $748.50 for a 30-day supply. Patients over 75 and those in the first 90 days of treatment should discuss the higher major bleeding risk with their clinicians before starting it.
The takeaway
Sunharbo adds a new tool for recurrent stroke prevention, but its bleeding trade-offs make careful patient selection essential. Anyone eligible should weigh the 26% stroke reduction against the risks in older patients and early treatment.
Further reading
For more on how doctors manage recurrence, see the Stroke section.
Source note: This article includes information reported by Juta MedicalBrief.






